Stock Analiz

Opus Genetics, Inc. IRD

Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026

$3.98Market cap $385M
Open the interactive analysis →

Opus Genetics, Inc. (IRD) is a healthcare company listed in the US with a market value of about $385M. In the twelve months to September 30, 2026 it had revenue of $8M and net income of -$137M, a net margin of -1726.7%.

Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -247%.

About Opus Genetics

Opus Genetics is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $3M in 2019 to $14M in 2025, growth of about 29.6% a year. It was profitable in 1 of the last 10 years in our data. Its share count rose by 202% over three years (dilution for shareholders). It spends 217% of revenue on research and development.

Score: 0.6 / 5

Value0/5
Future growth2/5
Track record0/5
Financial health1/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S48.6
P/B10.0
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-12.6%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)29.1%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-2101.1%
ROIC (5-yr avg.)-247.0%
Profitable years (of last 10)1
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$8M$14M$11M$19M$40M$589000$0$3M———
Net income-$137M-$50M-$58M-$10M$18M-$57M-$25M-$6M-$14M-$25M-$9M
Free cash flow-$49M—————-$7M-$4M———
EPS (diluted)$-1.48$-0.80$-2.15$-0.46$0.87$-3.82$-5.28$-2.17$-5.25$-11.06$-5.17
Net margin-1726.7%-349.3%-523.4%-52.4%44.9%-9625.3%—-205.6%———
ROIC—-234.3%-923.2%-16.7%38.7%-99.8%———-81.8%-76.0%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 17 analysts is $13.94, 250% above the current price; targets range from $8.00 to $20.00; the consensus rating is “Strong buy”; expected EPS is $-1.29 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does Opus Genetics pay a dividend?

Not currently.

Is Opus Genetics a good stock to buy?

We do not give buy or sell advice. Opus Genetics scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.